



Date: 12th August, 2026

BSE Limited

Dept. of Corporate Services,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
BSE Scrip Code - 541304

National Stock Exchange of India Limited

Dept. of Corporate Compliances,
Exchange Plaza, C-1 Block-G,
Bandra Kurla Complex,
Bandra (E) Mumbai- 400 051
NSE Symbol: INDOUS

Sub: Outcome of Board Meeting held on August 12, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Dear Sir,

Pursuant to the Regulation 30 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held on Wednesday, 12th August, 2026 at the registered office of the Company situated at 309, Shanti Mall, Satadhar Char Rasta, Opp. Navrang Tower, Sola Road, Ahmedabad, Gujarat, 380061 have considered and approved the following items of business:

1. The Board approved unaudited financial results of the company for the quarter ended 30th June, 2026 along with limited review reports obtained from the Auditor of the Company.

The Board Meeting commenced at 14.30 P.M. and concluded at 15:10 P.M.

You are requested to kindly take the same on record.

Thanking you,

For, Indo us Bio Tech Limited

DIMPY
DIVYANGBHAI
JOSHI

Ms. Dimpay Joshi

Company Secretary & Compliance officer





INDO US

BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Indo US Biotech Limited
CIN: LO1122GJ2004PLC043550
Regd. Office: 300, Shanti Mall, Sattedhar Char Road Opp. Narmad Tower, Bala Road, Ahmedabad, Gujarat 380061
Statement of Standalone Unaudited Financial Results for the quarter ended on June 30, 2026

Sr No	Particulars	Quarter Ended			Amount Rs. in Lakhs
		June 30, 2026	March 31, 2026	June 30, 2025	Year Ended March 31, 2026
1	Income :-				
2	Revenue from Operations	3,298.88	2,802.47	3,076.94	11,943.91
2	Other Income	12.36	2.15	0.15	5.42
	Total Income	3,311.24	2,804.62	3,077.11	11,949.33
3	Expenses :-				
	Purchase of stock in trade	524.19	308.37	715.14	3,116.91
	Production Expenses	982.55	3,440.93	885.95	7,836.94
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock in Trade				
	Employee Benefits Expense	1,210.26	(1,907.58)	813.24	(2,924.82)
	Finance Costs	32.34	43.36	32.06	142.13
	Depreciation & Amortisation	75.43	60.18	45.10	224.33
	Other Expenses	25.89	26.97	20.04	90.22
	Total Expenses	2,850.90	2,365.80	2,691.59	1,173.85
4	Profit(Loss) before exceptional items and tax	460.34	438.82	385.52	9,875.48
5	Exceptional items- Prior Period Items	307.70	237.82	481.99	1,392.02
6	Profit after exceptional items before tax	768.04	676.64	867.51	11,267.50
7	Tax Expense				
	Income Tax				
	- Current Year	4.73	25.13	6.95	54.97
	- Earlier Years Expenses/ (Written back)		3.82		3.18
	Deferred Tax Charge	(0.77)	11.70	4.80	21.51
	Total Tax Expense	3.96	40.65	11.75	79.73
8	Net Profit(Loss) for the period/year	764.08	636.02	855.76	11,187.77
9	Other comprehensive income (net of tax)				
	A. (i) Items that will not be reclassified to Profit and Loss				
	(ii) Income Tax and above		0.08	(0.29)	(0.78)
	B. (i) Items that will be reclassified to Profit and Loss		(0.02)	0.37	0.20
	(ii) Income tax relating to items that will be reclassified to Profit and Loss				
			0.06	(0.31)	(0.58)
10	Total Comprehensive Income	764.08	636.10	855.45	11,187.19
11	Pay-up equity share capital (face value of Rs.10 per share)	2,005.20	2,005.20	2,005.20	2,005.20
12	Other equity (excluding revaluation reserve)				
	EPS in Rs. (Face Value of Rs.10/- each)*				
	- Basic	1.51	0.98	2.35	6.54
	- Diluted	1.51	0.98	2.35	6.54
	- Adjusted	1.51	0.98	2.35	6.54
	*not annualised				

Notes :-

(1) The financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12.06.2026 and the Statutory Auditors of the Company have expressed an unmodified opinion on these results.

(2) The company is dealing in one major product segment, i.e. Seed Cultivation, Processing & Trading.

(3) There were no investor complaints pending received during the period under review.

(4) The figures have been regrouped wherever necessary.

Per. BHAGAT & ASSOCIATES
CHARTERED ACCOUNTANTS
FRN : 101100W

Rajkumar M. Bhagat
RAJKUMAR M. BHAGAT
PARTNER
M. NO. 036283

For and on behalf of Board of Directors



Jagdish D. Ajadiya
Jagdish D. Ajadiya
Managing Director
DIN: 01745951

Place: Ahmedabad
Date: 12.06.2026

UDIN: 26035263HPN3VXS758

Regd. Office
300, Shanti Mall, Sattedhar Cross Road,
Opp. Narmad Tower, Ahmedabad-380 061.
Tele Fax : +91-079-27491807,
Mobile : +91-9909043999

DBIR RECOGNITION IN HOUSE R&D UNIT
Factory Address :
Village-Bardol Kanthi,
Near Indira Nagar, Ta.-Dehgam,
Dist.-Gandhinagar, Gujarat.

E-mail : indousexim@gmail.com • Web : www.indousagriseeds.com





INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND YEAR TO DATE UNAUDITED STANDLONE IND- AS FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATION 2015, AS AMENDED.

LIMITED REVIEW REPORT

To,
The Board of Directors,
Indo US Bio-Tech Limited,
Ahmedabad, Gujarat

1. We have reviewed the accompanying standalone statement of unaudited financial results of **Indo US Bio-Tech Limited (CIN: L01122GJ2004PLC043550)** (the company) for the quarter ended 30th June 2026 ('The Statement') being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as amended (Listing Regulations).
2. This standalone statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34 -'Interim Financial Reporting' prescribed under section 133 of the Companies Act, 2013 (the Act) read with relevant rules issued there under and other recognized accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.



3. We conducted our review of the standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the standalone financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying standalone statement of unaudited financial results prepared in accordance with applicable accounting standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules made thereunder and other accounting principles generally accepted in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Bhagat & Associates
Chartered Accountants
FRN - 101100W



R.K. Bhagat

R.K Bhagat
(Partner)

Membership No - 035263
UDIN: 26035263HPNJVX5738

Place: Ahmedabad
Date: 12.08.2026